Home Cart Sign in  
Chemical Structure| 1616391-65-1 Chemical Structure| 1616391-65-1

Structure of EPZ015666
CAS No.: 1616391-65-1

Chemical Structure| 1616391-65-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

EPZ015666 (GSK3235025) is an orally active PRMT5 inhibitor with an IC50 of 22 nM.

Synonyms: GSK3235025

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of EPZ015666

CAS No. :1616391-65-1
Formula : C20H25N5O3
M.W : 383.44
SMILES Code : O=C(C1=NC=NC(NC2COC2)=C1)NC[C@H](O)CN3CC4=C(C=CC=C4)CC3
Synonyms :
GSK3235025
MDL No. :MFCD28411588
InChI Key :ZKXZLIFRWWKZRY-KRWDZBQOSA-N
Pubchem ID :90241673

Safety of EPZ015666

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • Histone Methyltransferase

    PRMT5, Ki:5 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
H929 cells 0 to 10 μM EPZ015666 significantly inhibited the proliferation of H929 cells in a dose-dependent manner PMC5871539
KMS11 cells 0 to 10 μM EPZ015666 significantly inhibited the proliferation of KMS11 cells in a dose-dependent manner PMC5871539
CD138+ pMM cells 5 μM 6 days EPZ015666 significantly inhibited the growth of CD138+ pMM cells PMC5871539

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice Carotid artery ligation model Oral 50 mg/kg Twice daily for 3 weeks EPZ015666 markedly attenuated neointimal formation induced by carotid artery ligation in mice. PMC10578915
C57BL/6j mice Pressure overload-induced heart failure model Oral 30 mg/kg/day Once daily for 8 weeks EPZ015666 significantly improved pressure overload-induced cardiac fibrosis and dysfunction, and suppressed cardiac hypertrophy and fibrosis-related gene expression. PMC10951424
NOD SCID mice GFP+-KMS11 xenograft model Oral 150 mg/kg Twice daily for 21 days EPZ015666 significantly inhibited tumor growth and prolonged survival in mice PMC5871539

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.61mL

0.52mL

0.26mL

13.04mL

2.61mL

1.30mL

26.08mL

5.22mL

2.61mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

[1]Duncan KW, Rioux N, Boriack-Sjodin PA, Munchhof MJ, Reiter LA, Majer CR, Jin L, Johnston LD, Chan-Penebre E, Kuplast KG, Porter Scott M, Pollock RM, Waters NJ, Smith JJ, Moyer MP, Copeland RA, Chesworth R. Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666. ACS Med Chem Lett. 2015 Dec 2;7(2):162-6. doi: 10.1021/acsmedchemlett.5b00380. PMID: 26985292; PMCID: PMC4753547.

[2]Chan-Penebre E, Kuplast KG, Majer CR, Boriack-Sjodin PA, Wigle TJ, Johnston LD, Rioux N, Munchhof MJ, Jin L, Jacques SL, West KA, Lingaraj T, Stickland K, Ribich SA, Raimondi A, Scott MP, Waters NJ, Pollock RM, Smith JJ, Barbash O, Pappalardi M, Ho TF, Nurse K, Oza KP, Gallagher KT, Kruger R, Moyer MP, Copeland RA, Chesworth R, Duncan KW. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat Chem Biol. 2015 Jun;11(6):432-7. doi: 10.1038/nchembio.1810. Epub 2015 Apr 27. PMID: 25915199.

[3]Gullà A, Hideshima T, Bianchi G, Fulciniti M, Kemal Samur M, Qi J, Tai YT, Harada T, Morelli E, Amodio N, Carrasco R, Tagliaferri P, Munshi NC, Tassone P, Anderson KC. Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. Leukemia. 2018 Apr;32(4):996-1002. doi: 10.1038/leu.2017.334. Epub 2017 Nov 21. PMID: 29158558; PMCID: PMC5871539.

[4]Braun CJ, Stanciu M, Boutz PL, Patterson JC, Calligaris D, Higuchi F, Neupane R, Fenoglio S, Cahill DP, Wakimoto H, Agar NYR, Yaffe MB, Sharp PA, Hemann MT, Lees JA. Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma. Cancer Cell. 2017 Oct 9;32(4):411-426.e11. doi: 10.1016/j.ccell.2017.08.018. Epub 2017 Sep 28. PMID: 28966034; PMCID: PMC5929990.

 

Historical Records

Categories